Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: IL-1β-primed mesenchymal stromal cells exert enhanced therapeutic effects to alleviate Chronic Prostatitis/Chronic Pelvic Pain Syndrome through systemic immunity

Fig. 2

IL-1β-primed MSCs showed better immune regulation ability and targeted migration ability than MSCs in vitro. A The expression of CXCR4, COX-2, TSG-6 and some other genes was checked by RT-qPCR in MSCs, and IL-1β-primed MSCs (n = 3 per group). B IL-1β-primed MSCs and MSCs expressing the CXCR4 protein were assessed by Western blotting (n = 3 per group). C The migration ability of IL-1β-primed MSCs and MSCs targeting CXCL12 was assessed by Transwell assays (n = 3 per group) (bar = 100 μm). D Inflammatory properties: Representative flow cytometry histograms of macrophages with CD206, Arg1, CD86, and iNOS in the saline, MSC, and IL-1β-primed MSC groups were detected by flow cytometry (n = 3 per group). E Statistical histograms of macrophages with CD206+, Arg1+, CD86+, and iNOS+ quantitative analysis in the saline, MSC, and IL-1β-primed MSC groups. F The proportion of CD4+FoxP3+ Treg cells in the saline, MSC, and IL-1β-primed MSC groups were detected by flow cytometry (n = 3 per group). Error bars indicate SD. *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page